Bacteriophage endolysins as a novel class of antibacterial agents

被引:267
作者
Borysowski, J
Weber-Dabrowska, B
Górski, A
机构
[1] Med Univ Warsaw, Inst Transplantol, Dept Clin Immunol, PL-02006 Warsaw, Poland
[2] Polish Acad Sci, Inst Immunol & Expt Therapy, Lab Bacteriophages, PL-53114 Wroclaw, Poland
关键词
bacteriophage; endolysin; antibiotic-resistance; infection;
D O I
10.1177/153537020623100402
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Endolysins are double-stranded DNA bacteriophage-encoded peptidoglycan hydrolases produced in phage-infected bacterial cells toward the end of the lytic cycle. They reach the peptidoglycan through membrane lesions formed by holins and cleave it, thus, inducing lysis of the bacterial cell and enabling progeny virions to be released. Endolysins are also capable of degrading peptidoglycan when applied externally (as purified recombinant proteins) to the bacterial cell wall, which also results in a rapid lysis of the bacterial cell. The unique ability of endolysins to rapidly cleave peptidoglycan in a generally species-specific manner renders them promising potential antibacterial agents. Originally developed with a view to killing bacteria colonizing mucous membranes (with the first report published in 2001), endolysins also hold promise for the treatment of systemic infections. As potential antibacterials, endolysins possess several important features, for instance, a novel mode of action, a narrow antibacterial spectrum, activity against bacteria regardless of their antibiotic sensitivity, and a low probability of developing resistance. However, there is only one report directly comparing the activity of an endolysin with that of an antibiotic, and no general conclusions can be drawn regarding whether lysins are more effective than traditional antibiotics. The results of the first preclinical studies indicate that the most apparent potential problems associated with endolysin therapy (e.g., their immunogenicity, the release of proinflammatory components during bacteriolysis, or the development of resistance), in fact, may not seriously hinder their use. However, all data regarding the safety and therapeutic effectiveness of endolysins obtained from preclinical studies must be ultimately verified by clinical trials. This review discusses the prophylactic and therapeutic applications of endolysins, especially with respect to their potential use in human medicine. Additionally, we outline current knowledge regarding the structure and natural function of the enzymes in phage biology, including the most recent findings.
引用
收藏
页码:366 / 377
页数:12
相关论文
共 95 条
[41]   Vincent Fischetti - following phages for life [J].
Larkin, M .
LANCET INFECTIOUS DISEASES, 2004, 4 (04) :246-249
[42]   Nasal colonization by Staphylococcus aureus in active, independent, community seniors [J].
Lee, YL ;
Cesario, T ;
Pax, A ;
Tran, C ;
Ghouri, A ;
Thrupp, LD .
AGE AND AGEING, 1999, 28 (02) :229-232
[43]  
Leiberman A, 1999, INT J PEDIATR OTORHI, V49, pS151
[44]   Population and evolutionary dynamics of phage therapy [J].
Levin, BR ;
Bull, JJ .
NATURE REVIEWS MICROBIOLOGY, 2004, 2 (02) :166-173
[45]   Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase [J].
Loeffler, JM ;
Nelson, D ;
Fischetti, VA .
SCIENCE, 2001, 294 (5549) :2170-2172
[46]   Synergistic lethal effect of a combination of phage lytic enzymes with different activities on penicillin-sensitive and -resistant Streptococcus pneumoniae strains [J].
Loeffler, JM ;
Fischetti, VA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (01) :375-377
[47]   Phage lytic enzyme Cpl-1 as a novel antimicrobial for pneumococcal bacteremia [J].
Loeffler, JM ;
Djurkovic, S ;
Fischetti, VA .
INFECTION AND IMMUNITY, 2003, 71 (11) :6199-6204
[48]   Evidence for a holin-like protein gene fully embedded out of frame in the endolysin gene of Staphylococcus aureus bacteriophage 187 [J].
Loessner, MJ ;
Gaeng, S ;
Scherer, S .
JOURNAL OF BACTERIOLOGY, 1999, 181 (15) :4452-4460
[49]   Three Bacillus cereus bacteriophage endolysins are unrelated but reveal high homology to cell wall hydrolases from different bacilli [J].
Loessner, MJ ;
Maier, SK ;
DaubekPuza, H ;
Wendlinger, G ;
Scherer, S .
JOURNAL OF BACTERIOLOGY, 1997, 179 (09) :2845-2851
[50]   C-terminal domains of Listeria monocytogenes bacteriophage murein hydrolases determine specific recognition and high-affinity binding to bacterial cell wall carbohydrates [J].
Loessner, MJ ;
Kramer, K ;
Ebel, F ;
Scherer, S .
MOLECULAR MICROBIOLOGY, 2002, 44 (02) :335-349